Fig. 2.
Evaluation of the in vitro antibacterial potential of CM derived from bovine fetal BM-MSCs and AT-MSCs against E. Coli ATCC25922. (A) First the antibacterial effect of CM derived from BM-MSCs, AT-MSCs, and FB was evaluated against E. Coli strain ATCC25922. (B) CM were concentrated (10-fold, CCM) with the aim of increasing their antibacterial capacity. (C) The in vitro antibacterial effect of CM from AT-MSCs, BM-MSCs and FBs pre-exposed to E. Coli (ACM) were in vitro evaluated against E. Coli. (D) ACM were also concentrated (10-fold) (CACM) and used against E. Coli. (E) The in vitro antibacterial effect against E. Coli of CM from AT-MSCs, BM-MSCs and FB was compared to each CCM. This was performed with the aim of verifying whether the effect of media concentration produced an increase in their antibacterial potential. (F) Comparative survival analysis of E. Coli strain ATCC25922 in CM and ACM from bovine fetal BM-MSCs, AT-MSCs and FBs. Superscripts (a, b,c) indicate significant differences (P < 0.05) between treatments within incubation hours.
